Mechanisms Underlying Methamphetamine-Induced Dopamine Transporter Complex Formation
Authors:
- Anthony J. BaucumABAnthony J. Baucum
- Jill L. KingJKJill L. King
- Kristen A. HornerKHKristen A. Horner
- Glen A. CookGCGlen A. Cook
- James W. GibbJGJames W. Gibb
- Diana G. WilkinsDWDiana G. Wilkins
- Glen R. HansonGHGlen R. Hanson
- Annette E. FleckensteinAFAnnette E. Fleckenstein
- 1 April 2009
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 329 (1) , 169-174
Abstract
Repeated, high-dose methamphetamine (METH) administrations cause persistent dopaminergic deficits in rodents, nonhuman primates, and humans. In rats, this treatment also causes the formation of high-molecular mass (greater than approximately 120 kDa) dopamine transporter (DAT)-associated complexes, the loss of DAT monomer immunoreactivity, and a decrease in DAT function, as assessed in striatal synaptosomes prepared 24 h after METH treatment. The present study extends these findings by demonstrating the regional selectivity of DAT complex formation and monomer loss because these changes in DAT immunoreactivity were not observed in the nucleus accumbens. Furthermore, DAT complex formation was not a consequence limited to METH treatment because it was also caused by intrastriatal administration of 6-hydroxydopamine. Pretreatment with the D2 receptor antagonist, eticlopride [S-(-)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide hydrochloride], but not the D1 receptor antagonist, SCH23390 [R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride], attenuated METH-induced DAT complex formation. Eticlopride pretreatment also attenuated METH-induced DAT monomer loss and decreases in DAT function; however, the attenuation was much less pronounced than the effect on DAT complex formation. Finally, results also revealed a negative correlation between METH-induced DAT complex formation and DAT activity. Taken together, these data further elucidate the underlying mechanisms and the functional consequences of repeated administrations of METH on the DAT protein. Furthermore, these data suggest a multifaceted role for D2 receptors in mediating METH-induced alterations of the DAT and its function.Keywords
This publication has 38 references indexed in Scilit:
- Differential regional effects of methamphetamine on dopamine transportEuropean Journal of Pharmacology, 2008
- Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptorThe EMBO Journal, 2007
- Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson’s diseaseNeuroscience, 2007
- Interactions of dopamine D1 and D2 receptor antagonists with D‐methamphetamine‐induced hyperthermia and striatal dopamine and serotonin reductionsSynapse, 2005
- High-Dose Methamphetamine Acutely Activates the Striatonigral Pathway to Increase Striatal Glutamate and Mediate Long-Term Dopamine ToxicityJournal of Neuroscience, 2004
- Antagonists of the Neurokinin‐1 or Dopamine D1 Receptors Confer Protection from Methamphetamine on Dopamine Terminals of the Mouse StriatumAnnals of the New York Academy of Sciences, 2004
- Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicityExperimental Neurology, 2004
- Methamphetamine Increases Dopamine Transporter Higher Molecular Weight Complex Formation via a Dopamine- and Hyperthermia-Associated MechanismJournal of Neuroscience, 2004
- Estimating Hydroxyl Radical Content in Rat Brain Using Systemic and Intraventricular Salicylate: Impact of MethamphetamineJournal of Neurochemistry, 1995
- Methamphetamine‐Induced Dopamine Overflow and Injury to Striatal Dopamine Terminals: Attenuation by Dopamine D1 or D2 AntagonistsJournal of Neurochemistry, 1993